 Connection
Grover Miller to Humans
This is a "connection" page, showing publications Grover Miller has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.728 |
|
|
|
-
Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
Score: 0.033
-
Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology. 2021 06 30; 458:152832.
Score: 0.032
-
Barnette DA, Schleiff MA, Datta A, Flynn N, Swamidass SJ, Miller GP. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. Toxicol Lett. 2021 Mar 01; 338:10-20.
Score: 0.031
-
Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. Drug Metab Dispos. 2021 02; 49(2):133-141.
Score: 0.031
-
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20).
Score: 0.031
-
Barnette DA, Schleiff MA, Osborn LR, Flynn N, Matlock M, Swamidass SJ, Miller GP. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology. 2020 07; 440:152478.
Score: 0.030
-
Barnette DA, Davis MA, Flynn N, Pidugu AS, Swamidass SJ, Miller GP. Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. Biochem Pharmacol. 2019 12; 170:113661.
Score: 0.029
-
Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP. CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. Chem Res Toxicol. 2019 06 17; 32(6):1151-1164.
Score: 0.028
-
Pouncey DL, Hartman JH, Moore PC, Dillinger DJ, Dickerson KW, Sappington DR, Smith ES, Boysen G, Miller GP. Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagul Fibrinolysis. 2018 Nov; 29(7):602-612.
Score: 0.027
-
Barnette DA, Davis MA, Dang NL, Pidugu AS, Hughes T, Swamidass SJ, Boysen G, Miller GP. Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches. Biochem Pharmacol. 2018 10; 156:10-21.
Score: 0.027
-
Kim SY, Jones DR, Kang JY, Yun CH, Miller GP. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Xenobiotica. 2019 Apr; 49(4):397-403.
Score: 0.026
-
Barnette DA, Johnson BP, Pouncey DL, Nshimiyimana R, Desrochers LP, Goodwin TE, Miller GP. Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases. Drug Metab Dispos. 2017 09; 45(9):1000-1007.
Score: 0.025
-
Hartman JH, Letzig LG, Roberts DW, James LP, Fifer EK, Miller GP. Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. Biochem Pharmacol. 2015 Oct 01; 97(3):341-9.
Score: 0.022
-
Pugh CP, Pouncey DL, Hartman JH, Nshimiyimana R, Desrochers LP, Goodwin TE, Boysen G, Miller GP. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. Arch Biochem Biophys. 2014 Dec 15; 564:244-53.
Score: 0.020
-
Hartman JH, Knott K, Miller GP. CYP2E1 hydroxylation of aniline involves negative cooperativity. Biochem Pharmacol. 2014 Feb 01; 87(3):523-33.
Score: 0.019
-
Hartman JH, Cothren SD, Park SH, Yun CH, Darsey JA, Miller GP. Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code. Bioorg Med Chem. 2013 Jul 01; 21(13):3749-59.
Score: 0.018
-
Hartman JH, Boysen G, Miller GP. Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica. 2013 Sep; 43(9):755-64.
Score: 0.018
-
Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 01; 6(3):157-64.
Score: 0.018
-
Hartman JH, Boysen G, Miller GP. CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos. 2012 Oct; 40(10):1976-83.
Score: 0.017
-
Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. Expert Opin Drug Metab Toxicol. 2011 Jul; 7(7):857-74.
Score: 0.016
-
Jones DR, Boysen G, Miller GP. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 01; 879(15-16):1056-62.
Score: 0.016
-
Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec; 4(4):213-9.
Score: 0.016
-
Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol. 2010 May 17; 23(5):939-45.
Score: 0.015
-
Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010 Feb; 42(1):55-61.
Score: 0.015
-
Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul; 22(7):1239-45.
Score: 0.014
-
Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos. 2008 Nov; 36(11):2211-8.
Score: 0.013
-
Miller GP. Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. Expert Opin Drug Metab Toxicol. 2008 Aug; 4(8):1053-64.
Score: 0.013
-
Collom SL, Laddusaw RM, Burch AM, Kuzmic P, Perry MD, Miller GP. CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem. 2008 Feb 08; 283(6):3487-3496.
Score: 0.013
-
Khojasteh SC, Argikar UA, Cheruzel L, Cho S, Crouch RD, Dhaware D, Heck CJS, Johnson KM, Kalgutkar AS, King L, Liu J, Ma B, Maw H, Miller GP, Seneviratne HK, Takahashi RH, Wang S, Wei C, Jackson KD. Biotransformation research advances - 2022 year in review. Drug Metab Rev. 2023 11; 55(4):301-342.
Score: 0.010
-
Wang S, Argikar UA, Cheruzel L, Cho S, Crouch RD, Dhaware D, Heck CJS, Johnson KM, Kalgutkar AS, King L, Liu J, Ma B, Maw H, Miller GP, Seneviratne HK, Takahashi RH, Wei C, Khojasteh SC. Bioactivation and reactivity research advances - 2022 year in review?. Drug Metab Rev. 2023 11; 55(4):267-300.
Score: 0.009
-
Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck CJS, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC. Bioactivation and reactivity research advances - 2021 year in review. Drug Metab Rev. 2022 08; 54(3):246-281.
Score: 0.009
-
Cui H, Carlson AS, Schleiff MA, Divakaran A, Johnson JA, Buchholz CR, Zahid H, Vail NR, Shi K, Aihara H, Harki DA, Miller GP, Topczewski JJ, Pomerantz WCK. 4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity. J Med Chem. 2021 07 22; 64(14):10497-10511.
Score: 0.008
-
Datta A, Flynn NR, Barnette DA, Woeltje KF, Miller GP, Swamidass SJ. Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. PLoS Comput Biol. 2021 07; 17(7):e1009053.
Score: 0.008
-
Khojasteh SC, Argikar UA, Driscoll JP, Heck CJS, King L, Jackson KD, Jian W, Kalgutkar AS, Miller GP, Kramlinger V, Rietjens IMCM, Teitelbaum AM, Wang K, Wei C. Novel advances in biotransformation and bioactivation research - 2020 year in review. Drug Metab Rev. 2021 08; 53(3):384-433.
Score: 0.008
-
Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metab Rev. 2020 08; 52(3):333-365.
Score: 0.008
-
Khojasteh SC, Bumpus NN, Driscoll JP, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Biotransformation and bioactivation reactions - 2018 literature highlights. Drug Metab Rev. 2019 05; 51(2):121-161.
Score: 0.007
-
Matlock MK, Tambe A, Elliott-Higgins J, Hines RN, Miller GP, Swamidass SJ. A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes. Chem Res Toxicol. 2019 08 19; 32(8):1707-1721.
Score: 0.007
-
Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev. 2018 08; 50(3):221-255.
Score: 0.007
-
Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computationally Assessing the Bioactivation of Drugs by N-Dealkylation. Chem Res Toxicol. 2018 02 19; 31(2):68-80.
Score: 0.006
-
Bostian AC, Maddukuri L, Reed MR, Savenka T, Hartman JH, Davis L, Pouncey DL, Miller GP, Eoff RL. Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19; 29(1):101-8.
Score: 0.006
-
Hartman JH, Miller GP, Boysen G. Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Toxicology. 2014 Apr 06; 318:51-8.
Score: 0.005
-
Freyaldenhoven S, Li Y, Kocabas AM, Ziu E, Ucer S, Ramanagoudr-Bhojappa R, Miller GP, Kilic F. The role of ERp44 in maturation of serotonin transporter protein. J Biol Chem. 2012 May 18; 287(21):17801-17811.
Score: 0.004
-
Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009 Jul; 37(7):1496-504.
Score: 0.003
-
Xiong Y, Patana AS, Miley MJ, Zielinska AK, Bratton SM, Miller GP, Goldman A, Finel M, Redinbo MR, Radominska-Pandya A. The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis. Drug Metab Dispos. 2008 Mar; 36(3):517-22.
Score: 0.003
-
Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2008 Jan; 324(1):139-48.
Score: 0.003
-
Guengerich FP, Miller GP, Hanna IH, Martin MV, L?ger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry. 2002 Sep 10; 41(36):11025-34.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|